Press Releases Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 01:16:52 2026-03-05 pm EST			5-day change	1st Jan Change
91.62 ^USD	-1.50%		-6.09%	-9.92%

Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
Feb. 19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026

Press Releases

Mar. 04	Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America	BU
Mar. 03	Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened	BU
Feb. 27	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
Feb. 19	Guardant Health: Q4 Earnings Snapshot	AQ
Feb. 19	Guardant Health : Q4 and Full Year 2025 Earnings Call	PU
Feb. 19	Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook	BU
Feb. 12	Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open	PR
Feb. 12	Single‑Reference Disclosures And The Motivation‑To‑Combine Requirement	AQ
Feb. 03	Guardant Health to Participate in Upcoming Investor Conferences	BU
Feb. 03	Largest Published Study of Molecular Residual Disease in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence after Surgery to Support Timely Treatment Decisions	AQ
Feb. 02	Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions	BU
Jan. 29	Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026	BU
Jan. 22	Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	BU
Jan. 19	Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	BU
Jan. 15	Guardant Health : JP Morgan Healthcare Conference	PU
Jan. 15	Guardant Health : Corporate Governance Guidelines (Corporate Governance Guidelines FINAL as of 10 22 2025)	PU
Jan. 15	Guardant Health : Compensation Committee Charter (Compensation Committee Charter FINAL as of 10 22 2025)	PU
Jan. 11	Guardant Health : Announces Preliminary Fourth Quarter and Full Year 2025 Results	PU
Jan. 11	Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results	BU
Jan. 08	Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families	BU
Dec. 30	Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening	AQ
Dec. 29	Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
Dec. 11	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.	BU
Dec. 09	Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy	BU
Dec. 05	Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	BU